BioMarin Pharmaceutical Inc. (BMRN)
1 Year Chart
"With two products on the market, and potentially a third to be launched by the end of 2007, BioMarin has transitioned from a product development-focused company to a fully integrated commercial biopharmaceutical company with growing revenues and an exciting product pipeline."
Here is the blah, blah on the company:
BioMarin Pharmaceutical, Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprised of approved products and various investigational product candidates. Approved products include Naglazyme (galsulfase), a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of genetic disease called mucopolysaccharidosis VI; and Aldurazyme that is used for the treatment of mucopolysaccharidosis I caused by the deficiency of a lysosomal enzyme called alpha-L-iduronidase. It also develops various investigational product candidates for the treatment of genetic diseases, including Kuvan (sapropterin dihydrochloride), formerly referred to as Phenoptin, a proprietary oral form of tetrahydrobiopterin (6R-BH4 or BH4), for the treatment of Phenylketonuria (PKU); and Phenylase (phenylalanine ammonia lyase), an enzyme substitution therapy for the treatment of phenylketonurics, who are not 6R-BH4 responsive. Further, BioMarin Pharmaceutical evaluates preclinical development of various other enzyme product candidates for genetic and other diseases, as well as an immune tolerance platform technology to overcome limitations associated with the delivery of existing pharmaceuticals. The company also holds rights to receive payments and royalties related to Orapred (prednisolone sodium phosphate) and Orapred ODT (prednisolone sodium phosphate orally disintegrating tablets) subsequent to the sublicense of North American rights. It sells its products to specialty pharmacies, hospitals acting as retailers, and pharmaceutical wholesalers in the United States, Japan, and European Union. BioMarin Pharmaceutical, Inc. has strategic alliance with Merck Serono. The company was founded in 1996 and is headquartered in Novato, California.
Bottom Line:
Using my "spec money", I will be
initiating a small position here.
Good luck everyone!
12 Comments:
Hi TG
I just read what this company does. I still have no idea what they do. Is the CEO of Biomarin also world record holder for the highest ever score in a game of Scrabble??
Good luck kind regards. Your man with his ear to the track. Richard
Richard,
I adore Scrabble!
Good choice, I have been tracking BMRN for a while. See:
http://investorshub.advfn.com/boards/board.asp?board_id=7982
Its a month or so behind, but still good info.
BMRN is going up!
Whatever happened to the biotech surfer dude from San Diego that used to comment on stuff like this.
Last stock he recommended was HGT, which was kind of a dog, and not in bio anything, unless you mean carbon based fuels...
Anon,
Thank you for your comment.
Jake,
I do see him surfing around, but have not talked with him in months. I wonder if I offended him in some way? :(
Oh gawd, I doubt it.
Prolly I did.
Heh heh.
"Prolly" - awwww! That is cute!
btw, how are your kids enjoying school?
They just started today.
"Enjoying" would not be the word I'd choose... first.
Jakey,
I thought your children were not old enough to hate school yet. ?
Another LT BMRN investor here...
Hi Bobo!
Good to see I have some company! :)
btw, what is it going to take for you to keep that VIX of yours down?
Post a Comment